Results 61 to 70 of about 414 (97)

Therapeutic Optimization of <i>Pseudomonas aeruginosa</i> Phages: From Isolation to Directed Evolution. [PDF]

Viruses
Bolognini S, Ferretti C, Campobasso C, Trovato E, Marchetti M, Rindi L, Tavanti A, Di Luca M.   +7 more
europepmc   +1 more source

Virus que matan bacterias: ¿el fin de los antimicrobianos? [PDF]

, 2007
Borie, M.V., Navarro, BQ.
core   +1 more source

Phage Therapy for Hospital-Acquired Respiratory Bacterial Infections: A Review. [PDF]

Open Respir Arch
Muñoz-Egea MC, Rodríguez A, Esteban J, García-Quintanilla M.   +3 more
europepmc   +1 more source

Isolation and characterization of novel Staphylococcus aureus bacteriophage Hesat from dairy origin. [PDF]

Appl Microbiol Biotechnol
Turchi B, Campobasso C, Nardinocchi A, Wagemans J, Torracca B, Lood C, Di Giuseppe G, Nieri P, Bertelloni F, Turini L, Ruffo V, Lavigne R, Di Luca M.   +12 more
europepmc   +1 more source

Fagoterapia como alternativa a infecciones bacterianas resistentes a antibióticos

Introduction: Bacterial resistance to antibiotics is a significant global public health issue. Bacteriophages, viruses that specifically target bacteria, represent a potentially effective alternative to combat these resistant infections. Objective: To evaluate phage therapy as a complement to antibiotics, analyze its mechanisms of action, determine its
openaire   +1 more source

Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. [PDF]

Nat Microbiol
Pirnay JP, Djebara S, Steurs G, Griselain J, Cochez C, De Soir S, Glonti T, Spiessens A, Vanden Berghe E, Green S, Wagemans J, Lood C, Schrevens E, Chanishvili N, Kutateladze M, de Jode M, Ceyssens PJ, Draye JP, Verbeken G, De Vos D, Rose T, Onsea J, Van Nieuwenhuyse B, Bacteriophage Therapy Providers, Bacteriophage Donors, Soentjens P, Lavigne R, Merabishvili M.   +27 more
europepmc   +1 more source

New materials and complications of prostheses in humans: situation in Spain. [PDF]

Rev Esp Quimioter
Vallet-Regí M, De Alarcón A, Gómez Barrena E, Planell JA, Silva J, Bouza E.   +5 more
europepmc   +1 more source

Contributos para o desenvolvimento de fagoterapias para infecções hospitalares por Pseudomonas aeruginosa multirresistentes

, 2011
As infecções hospitalares podem ser evitadas pelo controlo de determinados factores inerentes aos profissionais, material, ambiente. Neste momento, existe legislação própria de forma a regulamentar procedimentos que evitam a propagação da infecção e/ou dos agentes que a causam.
openaire   +1 more source

Estudios farmacocinéticos y farmacodinámicos de la fagoterapia

Farmacia Hospitalaria
Lucía Blasco, Inés Bleriot, Patricia Fernández-Grela, José Ramón Paño-Pardo, Jesús Oteo-Iglesias, María Tomás   +5 more
openaire   +1 more source